Tibremciclib或安慰剂联合氟维司群治疗内分泌治疗后激素受体阳性且ERBB2阴性晚期乳腺癌:一项随机临床试验
TIFFANY试验为双盲、安慰剂对照3期随机临床试验,在中国69个中心纳入274例内分泌治疗后进展的HR+/ERBB2-晚期乳腺癌女性患者,按2:1随机接受Tibremciclib(400 mg口服每日一次)联合氟维司群或安慰剂联合氟维司群。Tibremciclib组中位无进展生存期为16.5个月,安慰剂组为5.6个月(HR 0.37,95%CI 0.27-0.52,P<.001)。
要点
- Tibremciclib联合氟维司群较安慰剂联合氟维司群显著改善无进展生存期,中位16.5个月 vs 5.6个月(HR 0.37,95%CI 0.27-0.52,P<.001)。
- 在可测量病灶患者中,客观缓解率Tibremciclib组为45.6%,安慰剂组为12.9%(P<.001)。
- Tibremciclib组最常见的3级及以上治疗中出现的不良事件为中性粒细胞减少(15.2% vs 5.6%)、贫血(12.0% vs 4.4%)和低钾血症(12.0% vs 0%)。
核心结论
- Tibremciclib联合氟维司群较安慰剂联合氟维司群在HR+/ERBB2-晚期乳腺癌内分泌治疗后进展患者中与无进展生存期具有统计学显著且临床意义的改善相关。
- Tibremciclib联合氟维司群在该人群中显示出可控的安全性特征。
研究设计与样本
- TIFFANY试验为双盲、安慰剂对照3期随机临床试验,在中国69个中心开展,时间为2022年5月25日至2023年4月25日,本次分析数据截止日期为2024年3月31日。
- 纳入既往内分泌治疗期间进展且接受不超过1线化疗的HR+/ERBB2-晚期乳腺癌患者,共274例女性患者,中位年龄53.0岁(IQR 46.0-60.0)。
- 患者按2:1随机接受Tibremciclib(400 mg口服每日一次)联合氟维司群(184例,67.2%)或安慰剂联合氟维司群(90例,32.8%),直至疾病进展、死亡或治疗终止。
主要发现
- Tibremciclib组与安慰剂组分别发生80例和64例无进展生存事件,两组中位随访时间均为12.9个月。
- Tibremciclib联合氟维司群组中位无进展生存期为16.5个月(95%CI 12.8-16.6),安慰剂联合氟维司群组为5.6个月(95%CI 4.5-9.2),HR 0.37(95%CI 0.27-0.52),P<.001。
- 在可测量病灶患者中,Tibremciclib组客观缓解率为45.6%(95%CI 37.6%-53.7%),安慰剂组为12.9%(95%CI 6.1%-23.0%),P<.001。
- Tibremciclib组与安慰剂组最常见的3级及以上治疗中出现的不良事件分别为中性粒细胞减少(15.2% vs 5.6%)、贫血(12.0% vs 4.4%)和低钾血症(12.0% vs 0%)。
- Tibremciclib组无药物相关死亡,安慰剂组发生1例死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cyclin-dependent kinase (CDK) 4/6 inhibitors combined with endocrine therapy (ET) are now considered the standard treatment regimen for hormone receptor-positive (HR+) and ERBB2 (formerly HER2)-negative (ERBB2-) advanced breast cancer (ABC). Tibremciclib (BPI-16350), a novel CDK4/6 inhibitor, has demonstrated favorable tolerability and promising antitumor activity as a monotherapy or combined with fulvestrant among patients with HR+/ERBB2- ABC in a phase 1 trial. Further investigations are necessary to assess the efficacy and safety of tibremciclib. OBJECTIVE: To compare tibremciclib plus fulvestrant and placebo plus fulvestrant in terms of efficacy and safety among patients with HR+/ERBB2- ABC who exhibited disease progression after ET. DESIGN, SETTING, AND PARTICIPANTS: The TIFFANY trial was a double-blind, placebo-controlled, phase 3 randomized clinical trial of patients with HR+/ERBB2- ABC who had experienced progression while receiving prior ET and had received no more than 1 line of chemotherapy. This trial was conducted at 69 Chinese centers between May 25, 2022, and April 25, 2023. The data cutoff date for this analysis was March 31, 2024. INTERVENTIONS: Patients were randomly assigned to receive tibremciclib (400 mg, orally, once daily) plus fulvestrant or placebo plus fulvestrant at a 2:1 ratio until disease progression, death, or treatment discontinuation for various reasons. MAIN OUTCOMES AND MEASURES: The primary end point was investigator-assessed progression-free survival (PFS), and the secondary end points included the objective response rate, overall survival, and safety. RESULTS: A total of 274 female patients (median [IQR] age, 53.0 [46.0-60.0] years) were randomly assigned to receive tibremciclib plus fulvestrant (184 [67.2%]) or placebo plus fulvestrant (90 [32.8%]). Among these patients, 144 PFS events occurred (80 in the tibremciclib arm and 64 in the placebo arm), with a median follow-up of 12.9 months for both arms. Tibremciclib plus fulvestrant significantly improved PFS compared with placebo plus fulvestrant (median, 16.5 months [95% CI, 12.8-16.6] vs 5.6 months [95% CI, 4.5-9.2]; hazard ratio, 0.37; 95% CI, 0.27-0.52; P < .001). In patients with measurable disease, tibremciclib plus fulvestrant achieved an objective response rate of 45.6% (95% CI, 37.6%-53.7%) compared with 12.9% (95% CI, 6.1%-23.0%) in the placebo arm (P < .001). The most common grade 3 or higher treatment-emergent adverse events in the tibremciclib vs placebo arm were neutropenia (15.2% vs 5.6%, respectively), anemia (12.0% vs 4.4%, respectively), and hypokalemia (12.0% vs 0%, respectively). No drug-related deaths occurred in the tibremciclib arm, and 1 death occurred in the placebo arm. CONCLUSIONS AND RELEVANCE: The results of this randomized clinical trial suggest that tibremciclib plus fulvestrant was associated with statistically significant and clinically meaningful improvements in PFS compared with placebo plus fulvestrant. Furthermore, tibremciclib plus fulvestrant demonstrated a manageable safety profile in patients with HR+/ERBB2- ABC who experienced progression while receiving prior ET. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05433480.
引用
- Tao Z, Zhang J, Zheng Q, et al. Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical Trial. JAMA Oncol. 2025. PMID: 40742733. doi:10.1001/jamaoncol.2025.2092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。